Impact of components of metabolic syndrome on the risk of adverse renal outcomes in patients with atrial fibrillation: a nationwide cohort study

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

So-Ryoung Lee¹  Soonil Kwon¹  Hyo-Jeong Ahn¹  Seil Oh²  Eue-Keun Choi²  Gregory Y. H. Lip³  Jin-Hyung Jung⁴  Seung-Woo Lee⁴  Kyung-Do Han⁵ 

[1] Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea;Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea;Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Chest & Heart Hospital, Liverpool, United Kingdom;Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;Department of Medical Statistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea;Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea;

关键词: atrial fibrillation;    end-stage renal disease;    epidemiology;    metabolic syndrome;    risk factor;   

DOI  :  10.3389/fcvm.2023.1208979

 received in 2023-04-20, accepted in 2023-10-04,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundThe renal effect of metabolic syndrome components is unclear in patients with atrial fibrillation. This study aimed to investigate the association between metabolic syndrome components and incident end-stage renal disease among patients with atrial fibrillation.MethodsA total of 202,434 atrial fibrillation patients without prevalent end-stage renal disease were identified from the National Health Insurance Service database between 2009 and 2016. We defined the metabolic score range from 0 to 5 points such that a patient received every 1 point if the patient met each component listed in the diagnostic criteria of metabolic syndrome. The population was divided into 6 groups: MS0–MS5 for a metabolic score of 0–5, respectively. Multivariate Cox regression analysis was used to estimate the risks of end-stage renal disease.ResultsThere were 12,747, 31,059, 40,361, 48,068, 46,630, and 23,569 patients for MS0–MS5, respectively. Compared with MS0, MS5 had a higher CHA2DS2-VASc score (3.8 vs. 1.0) (P < .001). During a median follow-up of 3.5 years, compared with MS0, MS1–MS5 were associated with a gradually increasing incidence of end-stage renal disease, in relation to an increase in the metabolic score, (log-rank P < .001). After multivariate adjustment, a higher metabolic score was associated with a greater risk of incident end-stage renal disease: adjusted hazard ratio [95% confidence interval] = 1.60 [0.78–3.48], 2.08 [1.01–4.31], 2.94 [1.43–6.06], 3.71 [1.80–7.66], and 4.82 [2.29–10.15], for MS1–MS5, respectively.ConclusionsMetabolic syndrome components additively impacts the risk of incident end-stage renal disease among patients with atrial fibrillation.

【 授权许可】

Unknown   
© 2023 Kwon, Lee, Choi, Lee, Jung, Han, Ahn, Oh and Lip.